2 completed, 1 recruiting, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Nancy Lin, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Datopotamab Deruxtecan - Breast Cancer, Breast Cancer Female | Phase 2 | Recruiting | Nancy Lin, MD | 58 | 2024-01-08 | 2026-08-06 |
| Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB - HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases | Phase 2 | Completed | Nancy Lin, MD | 19 | 2018-05-21 | 2026-08-21 |
| ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases ZK219477 - Breast Cancer, CNS Disease | Phase 2 | Terminated | Nancy Lin, MD | 15 | 2007-07-01 | 2013-03-14 |
| Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Lapatinib, Herceptin - Breast Cancer | Phase 2 | Completed | Nancy Lin, MD | 87 | 2007-05-14 | 2024-12-19 |
Breast Neoplasms (3) · Brain Neoplasms (1) · Central Nervous System Diseases (1) · Triple Negative Breast Neoplasms (1)
Trastuzumab (2) · Lapatinib (1) · atezolizumab (1) · pertuzumab (1) · sagopilone (1)
United States (4)